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INTRODUCTION 
After halfa century of antibiotic use, infectious diseases 
still represent a major threat to human health world- 
wide. From the last report of the World Health 
Organization [l], infectious diseases account for 33% 
(17.3 million) of total annual deaths, among which 
acute respiratory tract infections represent more than a 
quarter (about 4.4 million deaths) [2]. Indeed, the 
respiratory tract is one of the main routes by which 
pathogens gain access to the body, and more than 
10 000 viable organisms are inhaled each day into the 
lungs. The nasopharynx is heavily colonized with a 
diverse group of microorganisms that can be aspirated 
into the lower airways, and bacterial dissemination from 
other body sites may also result in pulmonary infection. 
The lung maintains a highly sophisticated defense system 
which consists of structural, mechanical, secretory, 
humoral and cellular mechanisms [3,4]. Dyshnction of 
any of these mechanisms or insult by particularly 
virulent pathogens may increase the susceptibility of the 
host to pulmonary infection. In addition, there can be 
detrimental consequences of an exaggerated immune 
response, particularly the production of reactive oxygen 
radicals and the release of various proteases by phago- 
cytes. 
The sequential stages that are involved in bacterial 
clearance may be summarized as follows. Once inhaled 
or aspirated through the upper airways, the micro- 
organism is driven by the turbulent airflow and may 
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impact or stick to the respiratory epithelium. The 
mucociliary escalator usually sweeps away most of 
the inhaled particles. However, when this system is 
defective or ineffective, bacteria may adhere to the 
epithelium and gain access to the submucosa or 
encounter lymphoid tissues where a specific immuno- 
logic response may be initiated. If, despite the potent 
clearance mechanisms, microorganisms reach the 
alveolar surface, non-specific defense components of 
the alveolar milieu (opsonins, surfactant, IgG, comple- 
ment, cells, particularly macrophages) come into play. 
Macrophages form the first line of defense; oxidants, 
enzymes, nitric oxide and their bactericidal activity 
may be enhanced by cytokines produced by T- 
lymphocytes. They may release chemotactic factors 
(cytokines, eicosanoids) which, along with bacteria- 
derived products, attract polymorphonuclear neutro- 
phils (PMN), which have greater bactericidal and 
degradative responses than those of macrophages. 
Persistent infection leads to an extremely high immune 
response and subsequent pulmonary destruction. 
Parallel to the rapid non-specific response, a specific 
immune response develops, triggered by contact of the 
pathogens all along the respiratory tract with antigen- 
presenting cells (APCs) and bronchus-associated lym- 
phoid tissue (BALT). Elaboration of this response 
following antigen processing by APCs and transfer of 
the information to T-cells results in the production of 
specific antibodies and/or cytolytic T-cells and in the 
generation of memory T-cells, the basis for protection 
against reinfection with the same (or cross-reacting) 
pathogen. Respiratory protection may be afforded not 
only by contact or intravenous immunization, but also 
by oral immunization, following the migration of gut- 
derived T-cells to the pulmonary tract [5]. 
This review describes the various effectors of the 
host response, the dysfunction of host defenses and 
their consequences on pathogen colonization/multi- 
plication, gives some examples of bacterial virulence 
factors, and emphasizes the deleterious effects of the 
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inflammatory response itself. Table 1 summarizes the 
respiratory defense mechanisms. 
RESPIRATORY TRACT DEFENSES 
The mucociliary escalator 
The respiratory tract is made up of the upper airways 
(nasopharynx and larynx) and the conducting (lower) 
airways which begin at  the trachea and include 16 
generations of bronchi and respiratory bronchioles. 
Anatomic and mechanical barriers are completed by a 
potent particle removal mechanism mediated by the 
ciliated respiratory epithelium acting in concert with 
the secretory cells, the mucociliary transport system [6]. 
Each ciliated cell possesses about 200 cilia that beat at 
an average rate of 600 timedmin. The mucous blanket 
is produced by goblet cells, dispersed throughout the 
epithelium (approximately one goblet cell per five 
ciliated cells) and by mucous secretory cells and glands. 
Clara cells are non-ciliated secretory cells found only in 
the terminal bronchioles. The coordinated beating of 
the ciliated cells propels the overlying mucous blanket 
and other admixed particles towards the oropharynx. 
This system results in the clearance of 90% of particles 
larger than 2-3 pm in diameter. The exact physiologic 
and neurologic mechanisms that control ciliary func- 
tion and mucus production remain incompletely 
understood. 
Mucociliary dysfunction may result from a primary 
congenital defect- in the structure or function of the 
ciliated epithelium (ciliary dyskinesia), from a disease 
process such as viral or bacterial infection (destruction 
of the ciliated epithelium and/or mucus abnormality 
such as increased viscosity or decreased elasticity), 
asthma (exfoliation of the epithelium), cystic fibrosis, 
bronchiectasis (increased viscosity of mucus and super- 
infections) and chronic bronchitis (increased mucus 
secretion, decreased ciliated cells, metaplasia and thick- 
ening of the respiratory mucosa). Other causes of 
mucociliary dysfunction include pollutants (particularly 
cigarette smoke) and drugs (such as anesthetics, anti- 
histamines, expectorants, etc.). Defective mucociliary 
function allows pathogens to remain longer in the 
sinobronchial tree, with colonization, toxin secretion 
and attraction of PMNs, which results in amplification 
of the epithelial damage. 
Table 1 Respiratory defense mechanisms 
Factor Role 
~ ~~ 
Ainray dcfiferise merhariisms 
Anatomic barriers promoting airflow turbulence 
Airway reflexes: sneezing, cough, bronchoconstriction 
Mucociliary clearance: mucus secretion + ciliary beating 
Preferential mucosal adherence 
Immunologic defenses 
Immuiioglobulins 
- Upper ainvays (mainly secretory IgA) 
~ Mucoqa (mainly IgG) 
Lymphoid tissue 
Antigen-presenting cells (dendritic cells and possibly 
airway macrophages) 
rilvcolar t d r m  
Non-cellular components 
Alveolar lining fluid 
- Surfactant 
- Phospholipid<, neutral lipids 
- Enrymrs. proteins 
Albumin, transferrin 
~ al-Antitrypsiti 
- 1% (mainly IgG) 
~ Complcniciit 
Cclla 
Alveolar macrophagc\ (X.i%) 
Lymphocytes (10%) 
Neutrophils (2%). eotinophils (< 1%)) 
Particle impaction and deposition 
Particle expulsion 
Clearance of entrapped material 
Possible competition 
Viral neutralization. particle agglutindtioii, ciliary clearance 
Opsonin and complemeiit binding 
Possible reservoir of local immunity 
lnitiate immune response (antigen capture, processing. 
presentation to 7-cells) 
Non-immune opconin + imiiiuiiosuppre~cant 
Tensio-active 
Dcgradative 
Protcctioii (antiprotcasc) 
Opwnin,  complement binding 
Killing 
Itnniunc re\ponw + mediator releaw 
Sprcific immune re7ponx 
Defense + inflaiiimatiori 
.4r~plificatiorr qf df.f;.rises 
Phagocytr (mainly neutrophil) recruitment Defenw + inflammation 
(oxidant<, cytokines, proteases) 
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The alveolar unit 
In the alveolar milieu, airway defenses no longer 
operate. The alveolar epithelium is made up of two 
types of cells: type I and I1 pneumocytes [7]. Type I 
cells cover approximately 93% of the alveolar surface 
and type I1 cells are cuboidal with microvilli extending 
from their apical surface. They serve as progenitor cells 
for the alveolar epithelium and have prominent func- 
tions in host defenses. They produce surfactant which 
has a number of effects on immune and inflammatory 
responses. Most studies have focused on the opsonic 
activity of SP-A (surfactant protein A) and SP-D, which 
bind to alveolar macrophages via specific cell surface 
receptors and enhance the phagocytosis of a number 
of pathogens, e.g. Staphylococcus aureus, Pseudornonas 
tieruginosa, and Escherichia coli [8]. 
Along with dendritic cells, type I1 pneumo- 
cytes may serve as APCs: they express class I1 major 
histocompatibility complex and have the machinery 
necessary to process and present the antigen to 
T-cells. Type I1 cells also influence inflammatory and 
immune responses by synthesizing and secreting pro- 
inflammatory cytokines (interleukin-3 (IL-3), IL-8, 
chemokines), growth factors (granulocytemacrophage 
colony-stimulating factor (GM-CSF), tumor growth 
factor (TGF-P)), complement components (C2, C3, 
C4 and C5), prostaglandins and arachidonic acid 
(which can be metabolized by adjacent macrophages 
or neutrophils to leukotrienes). In addition, alveolar 
epithelial cells can interact with inflammatory cells 
through cell-cell contact by expressing cell adhesion 
molecules. Intercellular adhesion molecule-1 (ICAM- 
1), the natural ligand for leukocyte &-integrins, is 
expressed on the apical surface of type I cells, but 
can also be induced by hyperoxic insult on type I1 
cells. ICAM-1 has potential roles in the egress of 
inflammatory cells from the alveolar space, the co- 
stimulation required for T-cell activation and the 
destruction of the alveolar epithelium by inflammatory 
cells. In addition to the products secreted by pneumo- 
cytes, the alveolar lining fluid contains various mole- 
cules which are involved in alveolar defenses. The 
immunoglobulins found in the alveolar space are 
mainly IgG (about 15% of the total protein content), 
IgGl being quantitatively the most important (66%), 
followed by IgG2 (28%) and, to a lesser extent, 
IgG3 and IgG4 (5%). IgG favors opsonin-dependent 
phagocytosis and promotes the bactericidal activity of 
phagocytes. IgA is mostly found in the respiratory 
airways (10% of the protein content in the secretions 
recovered from trachea and bronchi, but only 5% in the 
alveoli). 
The cells normally present in the alveolar space are 
mainly alveolar macrophages (about 85% of the cells 
recovered in bronchoalveolar lavage (BAL) of healthy 
non-smokers). They are long-lived cells (months, years) 
and provide omnipresent, non-specific defense in the 
alveoli [9]. They are able to ingest and destroy most 
invading microorganisms by oxygen-dependent and 
-independent systems. They also possess secretory 
activities and release numerous mediators (cytokines, 
eicosanoids, enzymes) involved in the recruitment of 
blood phagocytes (monocytes and neutrophils) and in 
the activation of immune cells. Resident macrophages 
are able to clear low bacterial inocula. However, in 
cases of massive invasion, neutrophils (usually less than 
2% of the BAL cells) come into play and provide 
stronger bactericidal effects [lo]. The recruitment and 
activation of leukocytes are complex and dynamic 
processes which involve the coordinated expression 
of both pro- and anti-inflammatory cytokines. For 
example, whereas tumor necrosis factor (TNF) has 
been shown to mediate many of the detrimental 
pathophysiologic events that occur in sepsis, recent 
studies have provided compelling evidence in support 
of its importance in bacterial clearance from the lung 
Macrophage dysfunctions are generally secondary 
defects, following exposure to air pollutants (partic- 
ularly cigarette smoke), viral infection, anesthetics, 
chemotherapeutic and immunosuppressive agents and 
hyperoxia. Secondary macrophage dysfunction may 
also be associated with various clinical conditions 
such as viral infection, cancer, acidosis, pulmonary 
edema and uremia. In addition, various microorganisms 
have developed strategies to resist or even use macro- 
phages to persist and multiply intracellularly [12]. 
Macrophage and neutrophil dysfunction may also be 
found in some rare genetic disorders (e.g. chronic 
granulomatous disease, leukocyte adhesion deficiency). 
Congenital or acquired neutropenia (agranulocytosis) 
are high-risk factors for the development of severe 
infections, including pulmonary infections. 
[Il l .  
Specific immune effectors 
Development of a specific immune response implies 
antigen processing and presentation to T-cells by APCs 
and the activation of T-lymphocytes which secrete 
cytokines. Cytokines are important for B-cell differen- 
tiation into antibody-secreting plasma cells, the genera- 
tion of specific cytolytic T-cells and a pool of memory 
cells, readily activated by a second contact with the 
antigen. APCs in the respiratory tract comprise mainly 
dendritic cells, which represent approximately 1% of 
the epithelial cells in the mucosa of the large airways, 
and are also found in vascular walls, visceral pleura and 
alveolar septa. However, since dendritic cells do not 
extend to the epithelial surface, antigens must remain 
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attached and penetrate to the mucosal surface, a process 
which is counteracted by mucociliary clearance. In the 
alveolus, type I1 pneumocytes and macrophages have 
the capability of APCs. 
Lymphoid tissue in the respiratory tree includes 
tonsils and adenoids in the naso-oropharynx, lymph 
nodes around the trachea and bronchi (hilar lymph 
node complex), submucosal aggregates along the 
airways (BALT) and lymphocytes of the interstitial and 
alveolar pool. BALT is not as prominent in humans as 
in other animal species. In fact, it is not a constitutive 
structure in normal human lung but it can be formed 
under the influence of, as yet, undefined microbial 
factors. In rodents, the epithelium overlying the aggre- 
gate of one or two lymphoid follicles differs from 
nearby tissue, lacking cilia and goblet cells, and appears 
suitable for trapping and retaining substances. Follicles 
contain mainly lymphocytes (40-78% B-cells, 20% T- 
cells) and occasional macrophages. Among Ig-bearing 
cells, IgA and IgM predominate. After migrating along 
the respiratory tract, these cells produce local antibody 
for the mucosal surface. In the alveolar milieu, about 
10% of the cells recovered from BALT are lymphocytes 
(70% T-cells, mainly of the T-helper/inducer subset). 
Oral immunization has provided effective preven- 
tion of lung infection, mediated by the migration of 
memory and effector T-cells from the gut to the lung. 
Immune mechanisms at the various mucosal sites in the 
body interact through a common mucosal system, with 
the gut playing a central role by disseminating effector 
cells to the lung and other mucosal sites. This specific 
migration (homing) is dependent on tissue-specific 
addressins which are recognized by receptors on the 
lymphocyte membrane. Intestine-derived T-cells reside 
in the various lymphocyte compartments in the lung, 
where they may be reactivated upon exposure to 
antigens. 
Bacterial virulence and pulmonary infection 
Despite the wide array of pulmonary defenses, micro- 
organisms have evolved many strategies to persist in and 
colonize the respiratory tract. Some examples of 
virulence factors are presented in Table 2, and Table 3 
shows the main lower respiratory tract pathogens that 
are found in immunocompromised patients. Adherence 
is a primary mechanism by which microorganisms may 
persist in and colonize and finally infect the respiratory 
tract [13,14]. Bacteria adhere to epithelial cells via so- 
called ‘adhesins’. Risk factors for colonization include 
azotemia, endotracheal intubation, smoking, malnu- 
trition and ciliary dysfunction. Whereas Entero- 
bacteriaceae and group B streptococci preferentially 
colonize the nasopharynx, I? aeruginosa seems to 
interact selectively with the lower respiratory tract. 
Recently, it has been suggested that cytokines such as 
IL-1p and TNF-a, enhance Pseudomoms binding to 
tracheal cells by a PMN-dependent process, which is 
also enhanced by an epithelial cell-derived substance 
Another pathogenetic mechanism leading to 
adherence and colonization is the alteration of ciliary 
clearance. Many bacteria, directly or via their toxins, 
may impair ciliary function. Other mechanisms involve 
the destruction of IgA by proteases or resistance to 
phagocytosis mediated by aritiphagocytic structures 
such as a bacterial capsule [16]. In addition, the capacity 
~ 5 1 .  
Table 2 Some examples of virulence factors found in respiratory pathogens 
Virulence factor Effect Pathogen 
Receptor on cilia 1 Ciliary function Mycoplasmn, Bordetella 
Pyocyanin 1 Ciliary function P aerugirrosa 
I’ncumolysin 1 Ciliary function Streptococcus pnenmurriue 
IgA protease 1 IgA Streprococciis pnerrmoniae, Haeniophilus irzjliirnrae 
Neisscria uzeniyitidis, P aevqinosa 
Toxin? Tissue damage Lclyiorrella piierrmophila, Borderella pertussis 
l? aerrqinosa 
Capsule 1 I’hagocytosis Strepfotoccris pneumorriae, H. injircnzae 
l? aeruginosa 
lntracrllular paracltiqm PerqiTtence in macrophages Lqqionella prreumophila, Chlamydia, Borderello, 
Mycobacteria 
Pncuriiocytc inva~ion Blood dissemination Streptococcus ptreirmorrine 
Adhesin Colonization of tracheobronchial trer P aerriyiiiusu 
Colonization of nasopharynx Invasion Group B streptococci 
Enterobacteriaceae 
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Table 3 Main lower respiratory tract pathogens in 
irnmunocompromised patients 
Immune defect Pathogens 
T-lymphocyte Listeria, Nocardia, Salmonella, Legionella, 
Mycobacteria 
%lymphocyte Streptococcus pneumoniae, H.  inflnenzae 
Neutropenia 
Complement Streptococcus pneumoniae, H.  influenzae, 
J? aeruginosa, E. coli, Klebsiella 
Neisseria spp. 
Splenectomy Streptococcus pneumoniae, H. irtfluenzae, 
Staphylococcus aureus, E.  coli, 
Neisseria meningitidis 
of Myioplasma spp. to impair the phagocytosis of other 
bacteria in vitro emphasizes their possible role as 
copathogens with Chlamydia and other microorganisms 
[ 171. Avoidance of phagocytic bactericidal mechanisms 
leads to intraphagocytic persistence and replication 
[12]. Lastly, invasion of pneumocytes by pathogens, as 
recently demonstrated with Streptocoiiur pneumoniae 
(particularly the unencapsulated strains), may explain 
blood dissemination [ 181. 
An interesting pathway of pathogenicity by respira- 
tory pathogens has been described [19]. Many pathogens 
which reside within the alveolar macrophages, use the 
CD18 family of leukocyte adhesion molecules to gain 
access to the intracellular compartment. These molecules 
are also the predominant pathway used by leukocytes to 
enter the inflamedhnfected lung. An extreme example 
of molecular mimicry is given by Bordetella pertussis. This 
bacterium successhlly enters macrophages but also 
induces an extreme leukocytosis due to abnormal PMN 
trafficking. €3. pertussis presents two ligands to macro- 
phages, pertussis toxin (PT) and filamentous hema- 
glutinin (FHA), which act cooperatively to promote 
intracellular uptake. PT is a lectin which directs the 
adherence of B. pertussis to macrophages, but secreted 
PT, acting at a distance, upregulates CR3 (complement 
receptor 3), a P2-integrin which is recognized by FHA, 
and mediates uptake and survival of the bacteria in the 
macrophage. By contrast, secreted PT and FHA inhibit 
interaction of PMN with the endothelium, and the 
subsequent transmigration of this cellular effector within 
the inflamed lung. 
Phagocytes and the lung: a double-edged sword 
Although macrophage activity and neutrophil influx 
represent the major natural defenses against respiratory 
pathogens, the potential noxious effects of phagocytes, 
particularly PMNs, has received much attention 
[20-221. The inflammatory reaction which takes place 
in the early stages of pulmonary infection seems to 
cause little damage to the lung, due to partial activation 
of PMNs with a modest percentage (1-2%) of the cells 
delivered to an area of pneumonia migrating out into 
the air spaces [23]. However, full activation of this 
large intravascular pool of cells may result in wide- 
spread destruction of lung surface. The mediators of 
this destructive potential of PMNs are the reactive 
oxygen species produced after activation of a complex 
enzymatic system, NADPH oxidase, also a crucial 
mechanism in the bactericidal function of these cells, 
and proteinases which are released from intracellular 
stores (azurophilic, specific and tertiary granules). 
The most potent neutrophil mediator is neutro- 
phi1 elastase (NE), a 29-kDa serine protease capable of 
destroying most components of the extracellular 
matrix of the alveolar walls [24]. Other proteases, with 
elastolytic-like activity present in the lung, originate 
from neutrophils (cathepsin G and proteinase 3), 
alveolar macrophages (metalloproteinases, elastase and 
cathepsin L) or bacteria (e.g. I? aeruginosa elastase) [25]. 
In addition, phagocytes may release other proteinases 
which potentiate the action of true elastases by cleavage 
of extracellular matrix proteins which unmasks 
embedded elastin fibers (type 1 helper proteinases) 
[25]. The activity of most elastases and type 1 helper 
proteinases is normally controlled by proteinase in- 
hibitors. In particular, ai-proteinase inhibitor (ai-PI) 
regulates the activity of NE, while cathepsin G is 
controlled by a,-antichymotrypsin. &PI may be 
inactivated by various phagocyte and bacterial (e.g. 
Serratia marcesiens, l? aeruginosa, Staphyloioiius aureus, 
Legionella pneumophila) proteinases (type 2 helper 
proteinases) [25]. Oxidants produced by the phagocyte 
may also prevent proteinase action either by inactiv- 
ating a-PI or by activating latent metalloproteinase. 
In addition to its elastin fiber degradative activity, 
NE also has many deleterious effects which result in 
amplification of the inflammatory reaction and lung 
destruction (Figure 1) [22]. NE can injure the bronchial 
epithelium, increase mucus secretion and alter muco- 
ciliary clearance, resulting in increased adherence and 
multiplication of bacteria. This is further amplified by 
NE-mediated damage to Ig or complement proteins 
(C3b) with impairment of opsonophagocytosis. In 
addition, NE-inactivated al-antichymotrypsin may 
stimulate the synthesis of IL-6 and IL-8 in fibroblasts 
[22,26]. The latter cytokine, a potent chemoattractant, 
will amplify PMN recruitment, activation and protease 
release. 
CONCLUSIONS 
Appropriate antibiotic treatment based on bacterio- 
logic activity, pharmacokinetic properties (including 
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Figure 1 Inflammatory aniplification cascade. Once a pathogen has invaded the respiratory tract, neutrophils (PMNs) are 
recruited and activated. Degranulation of these cells and oxidant production then initiate an amplification loop as follows. 
Proteinases (mainly elastase) and reactive oxygen radicals destroy the tissues. Proteinases also cxert various detrimental effects 
such as destruction of the ciliated epithelium and stimulation of mucus secretion which results in decreased mucociliary 
clearance, enabling bacterial colonization and growth. In addtion, by destroying various opsonins (e.g. Ig and iCSb), 
proteinases impair phagocytosis, thus inhibiting bacterial clearance. Bacterial multiplication (X)  in turn generates signal5 
which attract more PMNs to the infection site, thus continuing the cycle. PMN recruitment is also increased by the 
production of interleukin-8 (IL-8), a chemokine, produced by fibroblasts stimulated with elastase-a1-antitrypypsin (al-AT) 
complex. ?=increase; L= decrease; +=enhancement; - =inhibition; X =growth. 
tissue concentration and cellular pharmacokinetics) and 
other pharmacologic properties remains the classical 
and essential therapeutic approach of  respiratory 
infections. N e w  approaches have, however, been 
suggested to  reduce the severity and mortality of these 
infectious diseases, o r  prevent their occurrence in at- 
risk patients. These are based o n  a better understanding 
of the pathophysiologic processes that have been briefly 
reviewed here. Among these new strategies, which are 
currently in use or  under development, is the use of  
substances which potentiate the antimicrobial function 
of phagocytes (aerosol delivery of various cytokines) [9] 
or  of compounds which should niodulate NE activity, 
such as natural o r  synthetic NE inhibitors 1221. Other  
strategies are still a matter of  debate, e.g. local antibiotic 
prophylaxis to  prevent airway colonization [13]. Future 
approaches may involve development of  a vaccine 
directed against adhesin [13], transient blockade of 
leukocyte recruitment [19,22] or  direct modulation of 
phagocyte functions. Among the many agents which 
can modifi. the host inflammatory response, much 
attention has been given to antibiotics [27]. Although 
this area of  research is controversial, the widely demon- 
strated anti-inflammatory activity of macrolides and its 
clinical implications in some respiratory inflammatory 
diseases with bacterial siiperinfections [28] has opened 
a new era in our  therapeutic control of infectious 
diseases. 
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